• Precision Medicine

  • Medical treatments are typically designed for the “average patient”. This “one-size-fits-all” approach often results in treatments being successful for some patients but not for others. The emergence of precision medicine aims to change this, by taking into account individual differences in people’s underlying biological characteristics. Precision medicine gives healthcare practitioners better tools to improve understandings of complex mechanisms underlying a patient’s health or disease, and to better predict which treatments will be most effective.

  • InsightRX Advantage

  • The technology underlying the InsightRX platform incorporates the principles of quantitative pharmacology and machine learning to provide an individualized understanding of a patient’s response to treatment. Quantitative pharmacology describes in mathematical and statistical language the relationship(s) between disease, drug action, and individual variability, which enables patient specific quantitative decision-making. The InsightRX platform delivers this technology in the form of easy to use clinical decision support tools at the point of care to help guide treatment decision-making.


  • Smarter Healthcare

  • The InsightRX platform guides treatment decisions at both the individual level and the population level. At the individual level, drug concentration and biomarker data are collected over-time to learn about the patient response and optimize treatment. At the population level, as more data is collected in larger patient populations, or in infrequently encountered patient populations, our pharmacological models and clinical algorithms that guide treatment recommendations will learn and will become more precise.


Platform Applications

  • Precision dosing

  • InsightRX leverages clinically validated pharmacokinetic models, patient physiology, pharmacogenomics, drug concentrations and biomarkers to optimize dosing. Real-time patient data and machine learning are combined to understand individual patient pharmacology and inform dose optimization.

  • Disease modeling

  • InsightRX leverages disease-based pharmacodynamic models to inform treatment decision making. Real-time patient data and machine learning are combined to simulate treatment and disease trajectories and inform treatment decision making.


  • Clinical analytics

  • InsightRX clinical analytics platform functionality ties together treatment strategies with patient outcomes. The data collected on the platform is leveraged to continuosly learn about patient populations, and provide patient benchmarking and dose/response metrics.


Our Team

Sirj Goswami, Founder

Holds a doctorate degree from the department of Bioengineering and Therapeutic Sciences at UCSF, with a research focus in genomics, pharmacokinetics and pharmacometrics. Sirj was a Discovery Fellow at UCSF and has over four years of industry experience at Genentech and Pfizer, working in drug development, spanning departments of biostatistics and clinical pharmacology. His passion lies in bringing genomics and advanced analytics to the forefront of healthcare, which he brings into practice as CEO of InsightRX.

Ron Keizer, Founder

Pharmacist with a PhD in pharmacometrics, Ron has (co-)authored 30+ peer-reviewed publications in pharmacometrics (the application of mathematical-statistical models in drug development or drug treatment). Ron is also a software engineer and the creator of Pirana, an IDE for applied modeling & simulation that is used by 500+ researchers in pharmaceutical industry and academia. After a post-doc at Uppsala University, Ron joined as a senior researcher at UCSF, and now leads the scientific and technological development at InsightRX.

Ranvir Mangat, Founder

A bioengineer by training Ranvir has over 5 years of experience as a pharmacometrics researcher in the Clinical Pharmacology Group at Genentech. Ranvir has led PK/PD analytics for a number of drug candidates in clinical development for early and late stage clinical trials, including global regulatory filings and post-marketing Phase IV studies for the blockbuster HER2 targeted drug franchise. His interests are in applying next generation software applications to enhance the therapeutic effectiveness and use of medications, and leverage real world clinical data to better understand performance. Ranvir is our COO at InsightRX.

Available Modules

  • Antibiotics

    • Vancomycin (neonates, children, adults)
    • Gentamicin (neonates)
    • Tobramycin (children, adults)
    • Amikacin (neonates)
    • Voriconazole
  • Transplantation / Oncology

    • Busulfan (children)
    • ATG (children)
    • Tacrolimus
    • Docetaxel myelosuppression
    • High-dose methotrexate
    • Imatinib / sunitinib / pazopanib
  • Other

    • Morphine (children)
    • Novel oral anti-coagulants (adults)

Recent Updates

  • Mar 9th, 2016InsightRX CTO/CSO Ron Keizer wins award from American Society for Clinical Pharmacology and Therapeutics (most-cited journal article).
    Jan 14th, 2016InsightRX partnering with UCSF and St. Jude's to individualize busulfan chemotherapy dosing for Gene Therapy trial in neonates.
    Dec 10th, 2015InsightRX presents at Plug&Play IoT/Healthcare EXPO See the presentation here.
    Dec 8th, 2015InsightRX featured in UCSF magazine, "The right dose: how pharmacy researchers are making medicine more precise" Read the article here.
    Nov 6th, 2015Insight selected to Exhibit at the 2015 ADA Healthtech Showcase.
    Feb 4th, 2015 InsightRX featured in Vatornews highlighting up-and-coming healthcare companies. Read the article here.
    May 31st, 2015InsightRX raises Seed funding round from Launchpad Digital Health and Plug&Play